Back to overview

Treatment of extraintestinal manifestations in inflammatory bowel disease.

Type of publication Peer-reviewed
Publikationsform Review article (peer-reviewed)
Publication date 2012
Author Lakatos Peter L, Lakatos Laszlo, Kiss Lajos S, Peyrin-Biroulet Laurent, Schoepfer Alain, Vavricka Stephan,
Project The role of SLC transporters in autophagy and inflammatory bowel disease
Show all

Review article (peer-reviewed)

Journal Digestion
Volume (Issue) 86 Suppl 1
Page(s) 28 - 35
Title of proceedings Digestion
DOI 10.1159/000341950


Inflammatory bowel disease (IBD) is a systemic disease associated with a large number of extraintestinal manifestations (EIM). EIM are present in 15-20% of patients with ulcerative colitis and in 20-40% of patients with Crohn's disease. The management of EIM is best provided by a multidisciplinary team, which includes specialists in the affected organ systems with training in the treatment of IBD. Therapeutic strategy is often empirical. This is explained by the paucity of randomized-controlled studies for the specific treatment of EIM in IBD and by the fact that treatment models are based on extrapolation from patients with similar conditions but without IBD. For most EIM, the mainstay of therapy is the treatment of the underlying active IBD. However, some EIM such as axial arthritis, pyoderma gangrenosum, uveitis and primary sclerosing cholangitis run a clinical course independent of IBD activity and need specific therapy (e.g. TNF antagonists in ankylosing spondylitis and skin manifestations). This review summarizes the conventional and novel (e.g. anti-TNF) treatment modalities, and the therapeutic implications for the management of extraintestinal symptoms in IBD, in order to assist clinicians in optimizing treatment strategies for IBD patients with EIM.